NR1H4 and metabolic dysfunction-associated steatotic liver disease: Recent studies have recognised FXR as an important therapeutic target for treating metabolic diseases [3, 10, 16] and the efficacy of FXR-targeting drugs has been tested in individuals with non-alcoholic fatty liver disease (NAFLD) [17].